The effect of topical Mometasone 0.1% and topical Hydrocortisone 1% in the prevention of acute radiation dermatitis of breast

Comparison of the efficacy of topical Mometasone 0.1% and topical Hydrocortisone 1% and placebo in the prevention of acute radiation dermatitis in breast cancer patients

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20180222038825N1

Enrollment

120

Registered

2018-03-28

Start date

2017-05-05

Completion date

Unknown

Last updated

2018-04-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

breast cancer. Malignant neoplasm of breast

Interventions

Intervention 1: Intervention group 1: Topical cream Mometasone 0.1%. The cream should be used once a day which is used after radiation. Also Patients will be instructed to wash skin with baby shampoo

Eligibility

Sex/Gender

Female

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients with breast cancer who had breast conservative surgery and should undergo breast radiation as adjuvant treatment

Exclusion criteria

Exclusion criteria: Past history of skin disease like eczema and psoriasis Past history of connective tissue disease like lupus erythematosus and sclerodermia recurrent or metastatic breast cancer Past radiation to the skin of treatment field

Design outcomes

Primary

Measure	Time frame
Radiation dermatitis grade. Timepoint: weekly after initiation of radiotherapy until the end of whole breast radiation. Method of measurement: Common Terminology Criteria for Adverse Events v4.0 (CTCAE) scale.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMahsa Kianinia

Esfahan University of Medical Sciences

mahsa.kianinia@gmail.com+98 31 3235 0210

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026